Propentofylline

CNS Drugs

Volumn 8, Issue 3, 1997, Pages 257-264

  Noble, Stuart ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; NERVE GROWTH FACTOR; PROPENTOFYLLINE;

ALZHEIMER DISEASE; DEGRADATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; HEADACHE; HEARTBURN; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEARNING; MEMORY; MICROGLIA; MULTIINFARCT DEMENTIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; VERTIGO;

EID: 0030867516     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708030-00008     Document Type: Review

References (44)

1. Fredholm BB, Lindström K. The xanthine derivative 1-(5′-oxohexyl)-3-methyl-7-propyl xanthine (HWA 285) enhances the actions of adenosine. Acta Pharmacol Toxicol Copenh 1986 Mar; 58: 187-92
2. Andiné P, Rudolphi KA, Fredholm BB, et al. Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia. Br J Pharmacol 1990 Aug; 100: 814-8
3. 2 receptors and NBMPR-sensitive nucleoside transporters. Nucleosides Nucleotides 1991; 10 (5): 1145-7
4. 2 receptors and nitrobnenzylthioinosine-sensitive nucleoside transporters: quantitative autoradiographic analysis. Eur J Pharmacol 1991 Sep 24; 202: 361-6
5. Ohkubo T, Mitsumoto Y, Mohri T. Characterization of the uptake of adenosine by cultured rat hippocampal cells and inhibition of the uptake by xanthine derivatives. Neurosci Lett 1991 Dec 9; 133: 275-8
6. Fredholm BB, Fastbom J, Kvanta A, et al. Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. Fundam Clin Pharmacol 1992; 6 (3): 99-111
7. Parkinson FE, Rudolphi KA, Fredholm BB. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen Pharmacol 1994 Oct: 25 (6): 1053-8
8. Nagata K, Ogawa T, Omosu M, et al. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phospho- diesterase activity. Arzneimittelforschung 1985; 35 pt II (7): 1034-6
9. Meskini N, Nemoz G, Okyayuz-Baklouti I, et al. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem Pharmacol 1994 Mar 2; 47: 781-8
10. McRae A, Rudolphi KA, Schubert P. Propentosylline depresses amyloid and Alzheimer's CSF microglial antigens after ischaemia. Neuroreport 1994 Jun 2; 5: 1193-6
11. McRae A, Schubert P, Ogata T, et al. Postischemic glial responses and amyloid accumulation are modified by propentofylline: neuroprotective pharmacon for Alzheimer's disease? [abstract no. 612]. Neurobiol Aging 1996; 17 Suppl. 4S: S152
12. Banati RB, Schubert P, Rothe G, et al. Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by propentofylline. J Cereb Blood Flow Metab 1994 Jan; 14: 145-9
13. Numagami Y, Marro PJ, Kubin JA, et al. Effect of propentofylline (PPF) on free radical generation during hypoxia in new-born piglets [abstract no. 2253]. Pediatr Res 1996 Apr; 39 (4 Pt 2): 378A
14. Miki S, Miki Y. Differential effects of propentofylline on the production of cytokines by peripheral blood mononuclear cells in vitro. Clin Ther 1991 Nov-Dec; 13 (6): 747-53
15. Schubert P, Ogata T, Rudolphi K. Depression of TNF-alpha release from microglial cells by adenosine and propentofylline [abstract no. 389]. J Cereb Blood Flow Metab 1997; 17 Suppl. 1: S718
16. DeLeo J, Toth L, Schubert P, et al. Ischemia-induced neuronal cell death, calcium accumulation, and glial response in the hippocampus of the Mongolian gerbil and protection by propentofylline (HWA 285). J Cereb Blood Flow Metab 1987 Dec; 7: 745-51
17. Kindy MS, Bhat AN, Bhat NR. Transient ischaemia stimulates glial fibrillary acid protein and vimentin gene expression in the gerbil neocortex, striatum and hippocampus. Mol Brain Res 1992; 13: 199-206
18. Si Q-S. Nakamura Y, Schubert P, et al. Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol 1996; 137: 345-9
19. Shinoda I, Furukawa Y, Furukawa S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem Pharmacol 1990 Jun 1; 39 (11): 1813-6
20. Nabeshima T, Nitta A, Fuji K, et al. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats. Gerontology 1994; 40 Suppl. 2: 46-56
21. Nitta A, Ogihara Y, Onishi J, et al. Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum. Eur J Pharmacol 1996; 307: 1-6
22. Park CK, Rudolphi KA. Antiischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. Neurosci Lett 1994 Sep 12; 178: 235-8
23. Haag P, Schneider T, Schabitz W-R, et al. Effect of propemofylline (HWA 285) on focal ischaemic stroke in rats. Influence of treatment and post-treatment duration on infarct size [abstract no. 645]. J Cereb Blood Flow Metab 1997; 17 Suppl. 1: S385
24. Johnson MP, McCarty DR, Chmielewski PA. Post-ischemia dosing with propentofylline (HWA 285) is neuroprotective in a temporary focal ischemia model [abstract no. 568]. J Cereb Blood Flow Metab 1997; 17 Suppl. 1: S666
25. Matsumoto K, Sakaki T, Kohmura E, et al. Amelioration of ischemic brain damage by the preischemic administration of propentofylline (HWA285) in a rat focal ischemia. Brain Res 1996; 723: 228-30
26. DeLeo J, Schubert P, Kreutzberg GW. Propentofylline (HWA 285) protects hippocampal neurons of Mongolian gerbils against ischemic damage in the presence of an adenosine antagonist. Neurosci Lett 1988 Feb 3; 84: 307-11
27. Dux E, Fastbom J, Ungerstedt U, et al. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res 1990 May 21; 516: 248-56
28. Kano T, Katayama Y, Kawamata T, et al. Propentofylline administered by microdialysis attenuates ischemia-induced hippocampal damage but not excitatory amino acid release in gerbils. Brain Res 1994 Mar 28; 641: 149-54
29. Miyashita K, Nakajima T, Ishikawa A, et al. An adenosine uptake blocker, propentofylline, reduces glutamate release in gerbil hippocampus following transient forebrain ischemia. Neurochem Res 1992 Feb; 17 (2): 147-50
30. Hirata H, Ogawa N, Haba K, et al. Effect of propentofylline on ischemia-induced loss of muscarinic cholinergic receptor binding in the gerbil hippocampus. Res Commun Chem Pathol Pharmacol 1992 Mar; 75 (3): 365-8
31. Fuji K, Hiramatsu M, Hayashi S, et al. Effects of propentofylline, a NGF synthesis stimulator, on alterations in muscarinic cholinergic receptors induced by basal forebrain lesion in rats. Neurosci Lett 1993 Feb 5; 150: 99-102
32. Grome JJ, Hofmann W, Gojowczyk G, et al. Effects of a xanthin derivative, propentofylline, on cerebral blood flow and glucose utilization in the rat. Brain Res 1996; 740: 41-6
33. Hudlicka O, Komarek J, Wright AJA. The effect of a xanthine derivative, 1-(5′oxohexyl)-3-methyl-7-propylxanthine (HWA 285), on heart performance and regional blood flow in dogs and rabbits. Br J Pharmacol 1981 Apr; 72: 723-30
34. Grome JJ, Rudolphi K, Harper AM. Cerebrovascular effects of a xanthine derivative propentofylline (HWA 285). Drug Dev Res 1985; 5: 111-21
35. Hudlicka O, Price S, Uhlmann E, et al. The effects of propentofylline (HW 285) on capillary density in the rabbit brain cortex [abstract no. 363]. J Cereb Blood Flow Metab 1997; 17 Suppl. 1: S760
36. Fuji K, Hiramatsu M, Kameyama T, et al. Effects of repeated administration of propentofylline on memory impairment produced by basal forebrain lesion in rats. Eur J Pharmacol 1993 Jun; 236: 411-7
37. Goto M, Demura N, Sakaguchi T. Effects of propentofylline on disorder of learning and memory in rodents. Jpn J Pharmacol 1987 Nov; 45: 373-8
38. Mielke R, Kittner B, Ghaemi M, et al. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. J Neurol Sci 1996; 141: 59-64
39. Mielke R, Ghaemi M, Kittner B, et al. Propentofylline enhances brain activation during memory stimulation in Alzheimer's disease - a PET study with 18-FDG [abstract]. Neurobiol Aging 1996; 17: S153
40. Huber M, Kittner B, Hojer C, et al. Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Flow Metab 1993 May; 13 (3): 526-30
41. Saletu B, Möller HJ, Grüberger J, et al. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 1990-91; 24: 173-84
42. Minami M, Arai H, Takahashi T, et al. A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders. Prog Neuropsych Biol Psych 1995 Jan; 19: 59-64
43. Marcusson J, Rother M, Kittner B, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dementia 1997; 8: 320-8
44. Kittner B, Koch G, Rossner M, et al. Effects of HWA285 on cognitive function, global function and activities of daily living in dementia. Congress of the International Psychogeriatric Association; 1995 Nov: Sydney